Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections.

J Chemother. 1999 Oct;11(5):391-5. Unique Identifier : AIDSLINE MED/20096247
Amenta M; Dalle Nogare ER; Colomba C; Prestileo TS; Di Lorenzo F; Fundaro S; Colomba A; Ferrieri A; Division di Malattie Infettive, Palermo, Italy.

Abstract: In HIV-1 infected patients severe enteritis and chronic diarrhea are often documented as a consequence of multiple opportunistic infections. We analyzed 48 HIV-1 positive patients for the presence of intestinal pathogenic protozoa. Patients with CD4 > or = 200/mm3 showed a higher prevalence of a single pathogenic protozoa than patients with CD4 < or =200/mm3, who showed the presence of multiple protozoal infections. Patients who proved positive for only a single protozoa, Cryptosporidium or Blastocystis, were also positive, by stool culture, for the presence of Proteus mirabilis (3 samples), Citrobacter freundii (3 samples), Escherichia coli (one sample) or Enterobacter cloacae (one sample). Treatment with rifaximin (600 mg, 3 times a day, for 14 days) was efficacious in resolving the clinical symptoms and clearing protozoan infections in HIV-1 infected patients with CD4 > or = 200/mm3, who presented enteric and systemic symptoms due to Criptosporidium or Blastocystis associated with enteropathogenic bacteria.
Keywords: CLINICAL TRIAL JOURNAL ARTICLE Adolescence Adult Animal AIDS-Related Opportunistic Infections/*DRUG THERAPY *Blastocystis hominis Blastocystis Infections/*DRUG THERAPY Child Cryptosporidiosis/*DRUG THERAPY *Cryptosporidium parvum Feces/PARASITOLOGY Female Human HIV-1 Male Middle Age Rifamycins/*THERAPEUTIC USE

KWDclinicaltrialjournalarticleadolescenceadultanimalaids-relatedopportunisticinfections/KWDdrugtherapyKWDblastocystishominisblastocystisinfections/KWDdrugtherapychildcryptosporidiosis/KWDdrugtherapyKWDcryptosporidiumparvumfeces/parasitologyfemalehumanhiv-1malemiddleagerifamycins/KWDtherapeuticuse
000330
A0030075

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .